miDIAGNOSTICS aims to develop diagnostic tests integrated in silicon chips. These will act as miniaturised labs, able to detect cells, proteins, nucleic acids, or small molecules from a small volume of body fluid. According to the company, the results and data from these tests will be available in minutes.
The emocha platform – a platform of digital mobile applications that streamline the continuum of care – will connect the products and their results to the laptops, tablets or smartphones of patients and caregivers, turning them into a mobile health solution for diagnostics at any point-of-need.
“emocha adds mobile data management to our diagnostic devices,” Hilja Ibert, CEO of miDIAGNOSTICS, explains. “They will complement our products with a mobile application, cloud infrastructure, and dashboards.
“The mobile application will give users easy access to a diagnostic device to initiate tests and view results on their mobile devices. The cloud infrastructure is the central hub transforming future products into mobile health solutions that links patient results to providers and health system electronic records. Finally, the dashboard will offer a customisable view of test results, allowing consolidation of tests and data analysis.”
